University of Kentucky
Trial Pipeline
Auditory Biofeedback Gait Training Individuals With Chronic Ankle Instability
NCT06868316
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
NCT05576350
Cannabis and Opioid Use Disorder
NCT05729932
OASIS: Peer Support for T2DM in Appalachia (Peer Participant)
NCT06336122
Ultrasound High BMI Study
NCT05052658
Development of a Mind Body Program for Obese Knee Osteoarthritis Patients With Comorbid Depression
NCT04334278
Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19
NCT04412330
Brain Exercises for Synaptic Plasticity
NCT03058055
Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies
NCT02048917
n-Acetylcysteine and Cocaine
NCT02141620
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
NCT01967381
Buspirone as a Candidate Medication for Methamphetamine Abuse
NCT01843205
A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction
NCT01561287
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
NCT01202370
Trichloroethylene (TCE) Exposure in an Industrial Population
NCT00839514
An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS
NCT00754273
A Prospective Study to Determine the Effectiveness of Reaming in Reducing Fat Emboli to the Lungs
NCT00327158
Oral Infections: Dietary Regulation of Local and Systemic Inflammatory Responses
NCT00632957
Impact of a Psychological Biofeedback-Relaxation Intervention on Clinical, Physical and Psychological Outcomes in Patients With Heart Failure
NCT00255931
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
| Phase 4 | 1 |
What the Pipeline for University of Kentucky Shows
According to the ClinicalTrials.gov registry, University of Kentucky is linked to 47 US clinical trials across every stage of research activity. Of those, 32 studies are currently recruiting — about 68% of the sponsor's indexed portfolio — and 15 are already marked complete, representing roughly 32% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Kentucky reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 7 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Kentucky is Methamphetamine Dependence with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.